Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
DNA, RNA & Cells
Filter     Order     Display # 
Date Item Title
30 May 2007 Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Paclitaxel and Carboplatin Trial
25 May 2007 La Jolla Pharmaceutical company reports Riquent(R) well tolerated in three studies at international lupus congress
25 May 2007 Inovio Biomedical’s DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
23 May 2007 Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
23 May 2007 Genzyme Announces Publication in PNAS Describing Novel Gene Therapy Approach for Niemann Pick Disease
23 May 2007 Topigen Presents New Data on Its Phase II Asthma Product, TPI ASM8, at the American Thoracic Society Annual Meeting
18 May 2007 Celladon and Targeted Genetics Initiate Phase I Clinical Trial of MYDICAR(TM) in Patients With Heart Failure
18 May 2007 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
17 May 2007 Cardium Initiates Phase 3 AWARE Clinical Study
15 May 2007 U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
10 May 2007 Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
08 May 2007 Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
08 May 2007 FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
08 May 2007 Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals
03 May 2007 Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infections
03 May 2007 FDA Clearance Received For Heart Attack Stem Cell Clinical Trial
03 May 2007 Expression Genetics, Inc. Receives Orphan Drug Grant from FDA for Clinical Development of EGEN-001 for Treatment of Ovarian Cancer
03 May 2007 Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
02 May 2007 Cardium Advancing Excellarate to Phase 2b Clinical Study
02 May 2007 University College London, Moorfields Eye Hospital and Targeted Genetics Initiate Phase I/II Clinical Trial of Gene Therapy for Childhood Blindness
01 May 2007 New Report Illuminates Ampligen(R)'s Unique Mechanism of Action
01 May 2007 Aastrom Initiates Adult Stem Cell Clinical Trial for Peripheral Arterial Disease
28 Apr 2007 Ark Therapeutics Grp - Regulatory Update
28 Apr 2007 CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma
27 Apr 2007 Sangamo BioSciences Initiates Additional Phase 2 Clinical Trial of Novel Therapy for Moderate to Severe Diabetic Neuropathy
25 Apr 2007 Ark Therapeutics Grp - Research Update
19 Apr 2007 Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
18 Apr 2007 ProNAi Announces Preclinical Success for PNT2258 Therapeutic – Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma
18 Apr 2007 Introgen's Intravenous Nanoparticle Gene Therapy Shows Activity in Stage IV Lung Cancer Patients
18 Apr 2007 Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
18 Apr 2007 Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
17 Apr 2007 Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
17 Apr 2007 Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients
17 Apr 2007 Regulatory Review Allows LCT Diabetes Clinical Program to Proceed
17 Apr 2007 Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis
14 Apr 2007 Ceregene Enrolling Patients For Phase 2 Clinical Trial Of Parkinson's Disease
12 Apr 2007 Novosom AG Acquires Exclusive Option for CD40-Targeted Antisense Inhibitors From Isis Pharmaceuticals
12 Apr 2007 Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial
05 Apr 2007 Genta Appeals FDA Decision on Genasense in CLL
31 Mar 2007 LCT reports major step forward for islet transplantation in diabetes patient
27 Mar 2007 Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC
26 Mar 2007 Osiris Therapeutics Announces Positive Results in Groundbreaking Stem Cell Trial to Treat Heart Disease
24 Mar 2007 Genta Announces Expectation of a Negative Opinion from the CHMP on Genasense(R) Application for Advanced Melanoma
23 Mar 2007 Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
21 Mar 2007 La Jolla Pharmaceutical Company (LJPC) Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
20 Mar 2007 Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel(TM)
15 Mar 2007 Transgene: First Patients Included in TG 1042 (Ad-IFNg) Phase II Clinical Trial in Cutaneous B-Cell Lymphoma
14 Mar 2007 Enzo Therapeutics Treats First Patient in Phase I/II Study of Antisense Gene Therapy for HIV-1 Infections
09 Mar 2007 La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
09 Mar 2007 TOPIGEN Initiates Expanded Phase II Trial of Inhaled TPI ASM8 in Patients With Asthma
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 251 - 300 of 591

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics